RxDoctor Payments Data

Richard Tyer, MD

Neurology · Tyler, TXNPI 1043238546

Payments from drug & device makers

$762in general payments, 2019–2025

Across 42 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$673
  • EMD Serono, Inc.$25
  • Novartis$17
  • UCB, Inc.$13
  • Supernus Pharmaceuticals, Inc.$12
  • Assertio Therapeutics, Inc.$11
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$74998%
  • Education$132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$762 in reported general payments places this provider in the 35th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$158,841
Medicare patients
440
Services billed
1,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5052$752,703
IngrezzaValbenazine Tosylate77$618,725
PanzygaImmun Glob G(Igg)-Ifas/Glycine29$216,960
GammakedImmune Globul G/Gly/Iga Avg 4614$105,470
CopaxoneGlatiramer Acetate13$72,174
Trokendi XrTopiramate12$11,491
VimpatLacosamide13$9,669
Levetiracetam266$7,317
Carbidopa-LevodopaCarbidopa/Levodopa320$5,694
Memantine Hcl352$5,365
Lacosamide36$5,278
Divalproex Sodium ErDivalproex Sodium42$3,252
Aspirin-Dipyridamole ErAspirin/Dipyridamole13$3,167
Desvenlafaxine Succinate ErDesvenlafaxine Succinate70$2,848
Gabapentin151$2,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$673$618,72577 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$12$11,49112 claims
UCB, Inc.Vimpat$13$9,66913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,246 neurology providers in Texas.

Other neurology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →